Biodexa Pharmaceuticals Plc (BDRX) Cash Flow Statement
Where BDRX’s cash came from and went, 2025
December 31, 2025 · British pounds- Cash from operations
- −£5.4M
- Capital expenditures
- £1,956
- Free cash flow
- −£5.4M
- Returned to shareholders
- —
- Change in cash
- £7.0M cash at year-end £8.5M
Drawn to scale: where the cash came from and how it was used. Hover for values.
BDRX operating cash flow, capex and free cash flow
BDRX cash flow trends, 2019–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −£6.5M2019 | −£5.4M2025 | — | |
| Capital expenditures | £319,0002019 | £1,9562025 | −57.2%/yr | |
| Free cash flow | −£6.8M2019 | −£5.4M2025 | — | |
| Free cash flow margin | −1,010.1%2019 | −1,860.6%2023 | −850.5 pts | |
| Stock-based compensation | −£34,0002019 | £170,0002025 | — | |
| Dividends paid | £02019 | £02025 | — | |
| Capex / revenue | 47.3%2019 | 69.0%2023 | +21.7 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BDRX cash flow by activity
BDRX net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
BDRX cash flow statement in British pounds
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Operating activities | |||||||
| Net income | −£6.4M | −£5.7M | −£7.1M | −£7.7M | −£5.5M | −£22.2M | −£10.1M |
| Depreciation & amortization | £184,857 | £254,000 | £283,000 | £343,000 | £403,000 | £1.2M | £1.3M |
| Stock-based compensation | £170,000 | £283,000 | £28,000 | £123,000 | £89,000 | −£404,000 | −£34,000 |
| Change in working capital | £1.7M | −£3.7M | −£49,000 | £520,000 | −£617,000 | −£1.6M | £1.8M |
| Other non-cash items | −£1.0M | −£3.3M | −£9,000 | −£378,000 | −£423,000 | £13.6M | £547,000 |
| Cash from operating activities | −£5.4M | −£12.3M | −£6.8M | −£7.0M | −£6.0M | −£9.3M | −£6.5M |
| Investing activities | |||||||
| Capital expenditures | −£1,956 | −£774,000 | −£263,000 | −£62,000 | −£320,000 | −£209,000 | −£319,000 |
| Investments (net) | — | −£598,000 | −£265,000 | −£220,000 | −£278,000 | £2.6M | −£3.8M |
| Acquisitions & other investing | −£656,295 | £774,000 | £263,000 | £62,000 | £320,000 | £209,000 | £319,000 |
| Cash from investing activities | −£658,251 | −£598,000 | −£265,000 | −£220,000 | −£278,000 | £2.6M | −£3.8M |
| Financing activities | |||||||
| Dividends paid | £0 | £0 | £0 | £0 | £0 | £0 | £0 |
| Net borrowing (repayment) | −£696,000 | £245,000 | −£188,000 | −£178,000 | −£215,000 | −£6.4M | £3.5M |
| Shares issued | £13.7M | £8.3M | £10.4M | £243,000 | £9.0M | £9.7M | £14.1M |
| Other financing | −£286,052 | £0 | −£13,000 | −£18,000 | −£15,000 | −£263,000 | £1.1M |
| Cash from financing activities | £12.8M | £8.6M | £10.2M | £47,000 | £8.8M | £3.1M | £18.7M |
| Summary | |||||||
| Net change in cash | £7.0M | −£4.3M | £3.1M | −£7.2M | £2.5M | −£3.4M | £8.6M |
| Cash at end of period | £8.5M | £1.7M | £6.0M | £2.8M | £10.1M | £7.5M | £10.9M |
| Free cash flow | −£5.4M | −£13.0M | −£7.1M | −£7.1M | −£6.3M | −£9.5M | −£6.8M |
| Free cash flow margin | — | — | −1,860.6% | −1,017.2% | −1,094.8% | −2,772.6% | −1,010.1% |
| Capex / revenue | — | — | 69.0% | 8.9% | 55.4% | 60.9% | 47.3% |
| Jun '26 | Dec '25 | Jun '25 | Mar '25 | Dec '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −£1.9M | −£2.6M | −£3.8M | −£2.4M | −£2.4M | −£3.3M | −£1.7M | −£3.5M | −£1.8M | −£3.6M | −£1.8M | −£4.6M |
| Depreciation & amortization | £80,588 | £48,697 | £140,609 | £116,206 | £118,000 | £136,000 | £68,000 | £140,000 | £70,000 | £143,000 | £71,500 | £161,000 |
| Stock-based compensation | — | — | £97,000 | £133,000 | £133,000 | £150,000 | £75,000 | £13,000 | £6,500 | £15,000 | £7,500 | £23,000 |
| Change in working capital | −£563,104 | £1.7M | £2.0M | −£2.4M | −£2.4M | −£1.3M | −£649,000 | £262,000 | £131,000 | −£104,000 | −£52,000 | £396,000 |
| Other non-cash items | −£2.3M | −£1.6M | −£1.8M | −£3.1M | −£2.8M | −£487,000 | −£243,500 | £151,000 | £75,500 | −£367,000 | −£183,500 | £506,000 |
| Cash from operating activities | −£4.6M | −£2.3M | −£3.3M | −£7.7M | −£7.5M | −£4.8M | −£2.4M | −£2.9M | −£1.5M | −£3.9M | −£1.9M | −£3.5M |
| Investing activities | ||||||||||||
| Capital expenditures | −£7,138 | −£61 | −£2,000 | −£774,000 | −£774,000 | −£4 | £0 | −£22,000 | −£11,000 | −£4,000 | −£2,000 | −£29,000 |
| Acquisitions & other investing | −£727,346 | −£308,869 | −£351,479 | £836,738 | £930,000 | −£753,996 | — | −£263,000 | — | £24,000 | £12,000 | −£174,000 |
| Cash from investing activities | −£734,484 | −£308,930 | −£353,479 | £62,738 | £156,000 | −£754,000 | — | −£285,000 | — | £20,000 | £10,000 | −£203,000 |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | — | — | — | — | — | — | — | — | — | −£47,500 | −£47,500 | −£47,500 |
| Shares issued | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 |
| Other financing | −£63,247 | £7.2M | £5.7M | £4.1M | £3.9M | £4.6M | £2.3M | £4.0M | £2.0M | £6.3M | £3.2M | £172,500 |
| Cash from financing activities | −£63,247 | £7.2M | £5.7M | £4.1M | £3.9M | £4.6M | £2.3M | £4.0M | £2.0M | £6.3M | £3.1M | £125,000 |
| Summary | ||||||||||||
| Net change in cash | −£5.5M | £4.4M | £4.0M | −£3.4M | −£5.1M | £5.1M | −£458,000 | £372,000 | £372,000 | £1.2M | £1.2M | −£1.8M |
| Cash at end of period | £3.3M | £8.5M | £4.0M | £1.7M | £1.7M | £5.1M | −£458,000 | £372,000 | £372,000 | £1.2M | £1.2M | −£1.8M |
| Free cash flow | −£4.6M | −£2.3M | −£3.3M | −£8.2M | −£8.2M | −£4.8M | −£2.4M | −£3.0M | −£1.5M | −£3.9M | −£1.9M | −£3.5M |
| Free cash flow margin | — | — | — | — | — | — | — | −3,574.7% | −3,574.7% | −1,303.7% | −1,303.7% | −1,531.6% |
| Capex / revenue | — | — | — | — | — | — | — | 26.5% | 26.5% | 1.3% | 1.3% | 12.6% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in British pounds as reported; data from EODHD.
BDRX cash generation
In fiscal 2025 (ended December 31, 2025), Biodexa Pharmaceuticals Plc generated -£5.4 million of cash from operations and spent £0.0 million on capital expenditures, leaving free cash flow of -£5.4 million. Cash and equivalents rose by £7.0 million over the year.
Related: BDRX income statement, BDRX balance sheet. See the BDRX stock overview for the latest quote and news.
BDRX cash flow FAQ
What is Biodexa Pharmaceuticals Plc's free cash flow?
Biodexa Pharmaceuticals Plc's free cash flow was -£5.4 million in fiscal 2025: -£5.4 million of operating cash flow minus £0.0 million of capital expenditures It was -£13.0 million a year earlier..
How much cash does Biodexa Pharmaceuticals Plc generate from operations?
Biodexa Pharmaceuticals Plc generated -£5.4 million of cash from operating activities in fiscal 2025.
How much does Biodexa Pharmaceuticals Plc spend on capital expenditures?
Biodexa Pharmaceuticals Plc spent £0.0 million on capital expenditures in fiscal 2025, compared with £0.8 million the year before.